List view / Grid view
This study demonstrates the ease, simplicity and speed of performing multiple conditions in one experiment using Ambr 15 Cell Culture by assessing five different media compositions on two different clones.
16 December 2021 | By Eurofins DiscoverX and Sanford Burnham Prebys Medical Discovery Institute
Watch this on-demand webinar to learn about orphan GPCRs as drug targets and the challenges related to lead identification.
In this ebook, find an article on 3D tissue cultures from biopsy samples to evaluate the preservation of tissue-typical protein expressions as well as a piece on a new process analytical technology (PAT) system to assess N-glycosylation during upstream cell culture bioprocessing.
Here, we round up some of the key takeaways from the expert panel discussions at the Cell & Gene Therapy Advancements Online Summit.
Everest Medicines and Providence Therapeutics have started working on a new version of COVID-19 vaccine specifically targeting the new Omicron variant.
In this article, Drug Target Review's Victoria Rees explores a new method that could enable powerful immune cells to be produced in large quantities to treat a range of cancers.
Biologics solutions from discovery to manufacturing.
The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM.
Tune in to this podcast to learn about AAV vectors for gene therapy delivery and engineering CAR T cells against solid tumours.
Treatment with Viking Therapeutics' dual agonists resulted in mean reductions in body weight of up to 27 percent compared to semaglutide-treated animals.
This whitepaper overviews phenotypic and functional characterisation of CAR-T cells with advanced flow cytometry and live-cell analysis.
Medicenna's IL-2 super-agonist, MDNA11, successfully induced antitumour cells in animal models, a pre-clinical study has revealed.
The discovery of a link between the human leukocyte antigen (HLA) and genital warts may lead to mRNA-based vaccines against HPV and other diseases.
A $5 million grant will be used to train students in stem cell research to contribute towards new stem cell-based therapeutics.
An interview with Dr Arun Srivastava about his research into safe and effective AAV vectors that do not prompt a reaction from the immune system.
